Biopharma financing during the second quarter of 2023 totaled $23.8bn from 268 deals. The venture financings category made up the greatest proportion (27%) of the aggregate Q2 financing dollars (see Exhibit 1), with 91 early- and late-stage VC rounds together totaling $6.4bn.
There were 67 biopharmas together raising $3.4bn (14% of the total Q2 dollars) through early-stage rounds and 24 companies bringing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?